These findings might have some theoretical BRAF V600E mutation is generally accepted as a reliable prognostic marker for papillary carcinoma and more importantly, has been found to be an independent predictor of treatment failure and tumor recurrence, even in patients with low stage disease [38-41]. This evidence concerns the gene BRAF and neoplasm.